Myasthenia Gravis Pipeline 2024: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights By DelveInsights | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myasthenia Gravis pipeline constitutes 20+ key companies continuously working towards developing 22+ Myasthenia Gravis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Myasthenia Gravis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Myasthenia Gravis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myasthenia Gravis Market.

Some of the key takeaways from the Myasthenia Gravis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Myasthenia Gravis treatment therapies with a considerable amount of success over the years.

*
Myasthenia Gravis companies working in the treatment market are Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others, are developing therapies for the Myasthenia Gravis treatment

*
Emerging Myasthenia Gravis therapies in the different phases of clinical trials are- Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others are expected to have a significant impact on the Myasthenia Gravis market in the coming years.

*
In December 2024, Cartesian Therapeutics has released updated efficacy and safety findings from its Phase IIb trial evaluating Descartes-08, an mRNA cell therapy candidate for generalized myasthenia gravis (MG). The results showed sustained responses at the 12-month mark. The trial (NCT06038474) was a double-blind, placebo-controlled, crossover study conducted in an open-label format, involving 36 severely symptomatic, heavily pre-treated patients. Half of the participants received a placebo, while the other half were treated with Descartes-08. Both groups underwent six weekly outpatient infusions without the need for preconditioning chemotherapy.

*
In December 2024, Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced the initiation of enrollment for the Ntrust-2 trial and the IND clearance for an investigator-sponsored trial (IST) of NKX019. NKX019 is Nkarta's allogeneic, CD19-directed CAR NK-cell therapy, which will be evaluated in patients with myasthenia gravis (MG). The multi-center Ntrust-2 trial will assess NKX019 across three cohorts, including systemic sclerosis (SSc/scleroderma), idiopathic inflammatory myopathy (IIM/myositis), and ANCA-associated vasculitis (AAV). The IST will be conducted by researchers at the University of California, Irvine, and the University of Kansas Medical Center.

*
In August 2024, Merck KGaA (Merck) administered the first dose in a Phase III clinical trial evaluating oral Cladribine for the treatment of generalized myasthenia gravis (gMG), a rare neuromuscular condition. Named MyClad, this global, randomized, double-blind, placebo-controlled study is designed to assess the efficacy and safety of Cladribine capsules in comparison to a placebo.

*
In June 2024, Johnson & Johnson (NYSE: JNJ) announced positive results from the Phase 3 Vivacity-MG3 study of nipocalimab in patients with generalized myasthenia gravis (gMG). Patients receiving nipocalimab alongside standard care (SOC) showed superior improvement over those receiving placebo plus SOC, as measured by the primary endpoint of the MG-ADL score improvement from baseline over 24 weeks. These findings are part of a presentation and one of eight abstracts Johnson & Johnson will present at the European Academy of Neurology (EAN) 2024 Congress and will be included in regulatory submissions later this year.

*
In January 2024, Cartesian Therapeutics' Descartes-08, an investigational autologous mRNA-engineered chimeric antigen receptor T-cell (CAR-T) therapy for autoimmune diseases like myasthenia gravis (MG), has shown clinically significant improvements in the phase 2a part of a clinical trial (NCT04146051) for MG. All 7 patients in the phase 2a portion, treated with a single infusion of Descartes-08 weekly for 6 weeks, demonstrated substantial and lasting clinical improvements in MG Composite, MG Activities of Daily Living, Quantitative MG scores, and Quality of Life 15-revised assessments at 9 months post-treatment.

*
In January 2024, RYSTIGGO Registered (rozanolixizumab-noli) is a specialized treatment for adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. Created by the Belgian biopharmaceutical company UCB, RYSTIGGO is provided in a single-dose vial containing 280mg/2ml (140mg/ml) of a colorless to light brownish-yellow solution, intended for subcutaneous injection.

Myasthenia Gravis Overview

Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. The name, which translates to "grave muscle weakness," reflects the primary symptom of the condition. MG occurs when the immune system produces antibodies that interfere with the communication between nerves and muscles.

Get a Free Sample PDF Report to know more about Myasthenia Gravis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight [https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Myasthenia Gravis Drugs Under Different Phases of Clinical Development Include:

*
Povetacicept: Alpine Immune Science

*
TOL 2: Toleranzia

*
MuSK-CAART: Cabaletta Bio

*
RLYB116: Rallybio

*
ALXN2050: Alexion Pharmaceuticals

*
TAK-079: Takeda

*
Descartes-08: Cartesian Therapeutics

*
Telitacicept: RemeGen

*
Inebilizumab: Horizon Therapeutics

Myasthenia Gravis Route of Administration

Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Infusion

*
Intradermal

*
Intramuscular

*
Intranasal

*
Intravaginal

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Molecule Type

Myasthenia Gravis Molecule Type

Myasthenia Gravis Products have been categorized under various Molecule types, such as

*
Vaccines

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Product Type

Myasthenia Gravis Pipeline Therapeutics Assessment

*
Myasthenia Gravis Assessment by Product Type

*
Myasthenia Gravis By Stage and Product Type

*
Myasthenia Gravis Assessment by Route of Administration

*
Myasthenia Gravis By Stage and Route of Administration

*
Myasthenia Gravis Assessment by Molecule Type

*
Myasthenia Gravis by Stage and Molecule Type

DelveInsight's Myasthenia Gravis Report covers around 22+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Myasthenia Gravis product details are provided in the report. Download the Myasthenia Gravis pipeline report to learn more about the emerging Myasthenia Gravis therapies [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Myasthenia Gravis Therapeutics Market include:

Key companies developing therapies for Myasthenia Gravis are - CuraVac, Grifols SA, Immunovant, Mitsubishi Tanabe Pharma, Novartis, Alexion Pharmaceutical, Argenx, Astellas Pharma, UCB Pharma, Bausch Health, and others.

Myasthenia Gravis Pipeline Analysis:

The Myasthenia Gravis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Myasthenia Gravis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myasthenia Gravis Treatment.

*
Myasthenia Gravis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Myasthenia Gravis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myasthenia Gravis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myasthenia Gravis drugs and therapies [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myasthenia Gravis Pipeline Market Drivers

*
Increasing prevalence of Myasthenis gravis, growing awareness regarding the myasthenia gravis diagnosis options, surge in geriatric population with autoimmune disease are some of the important factors that are fueling the Myasthenia Gravis Market.

Myasthenia Gravis Pipeline Market Barriers

*
However, limited reimbursement policies, high cost associated with the treatment and other factors are creating obstacles in the Myasthenia Gravis Market growth.

Scope of Myasthenia Gravis Pipeline Drug Insight

*
Coverage: Global

*
Key Myasthenia Gravis Companies: Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others

*
Key Myasthenia Gravis Therapies: Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others

*
Myasthenia Gravis Therapeutic Assessment: Myasthenia Gravis current marketed and Myasthenia Gravis emerging therapies

*
Myasthenia Gravis Market Dynamics: Myasthenia Gravis market drivers and Myasthenia Gravis market barriers

Request for Sample PDF Report for Myasthenia Gravis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Myasthenia Gravis Report Introduction

2. Myasthenia Gravis Executive Summary

3. Myasthenia Gravis Overview

4. Myasthenia Gravis- Analytical Perspective In-depth Commercial Assessment

5. Myasthenia Gravis Pipeline Therapeutics

6. Myasthenia Gravis Late Stage Products (Phase II/III)

7. Myasthenia Gravis Mid Stage Products (Phase II)

8. Myasthenia Gravis Early Stage Products (Phase I)

9. Myasthenia Gravis Preclinical Stage Products

10. Myasthenia Gravis Therapeutics Assessment

11. Myasthenia Gravis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Myasthenia Gravis Key Companies

14. Myasthenia Gravis Key Products

15. Myasthenia Gravis Unmet Needs

16 . Myasthenia Gravis Market Drivers and Barriers

17. Myasthenia Gravis Future Perspectives and Conclusion

18. Myasthenia Gravis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myasthenia-gravis-pipeline-2024-comprehensive-clinical-trials-and-therapies-analysis-with-key-moa-and-roa-insights-by-delveinsights-alpine-immune-science-toleranzia-cabaletta-bio-rallybio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.